Nursefriendly.com: biotechnology

Wednesday, November 17, 2010

Grifols has been working in the fields of transfusion, blood banking and clinical analysis for more than 70 years. Founded in 1940 by Dr. J.A. Grifols Roig, three generations of the Grifols family have led the company ever since. Our Grifols S.A. President, Victor Grifols, ensures that our company will always remain focused on what matters most - people. This dedication to the progress of healthcare for humankind has led to the distribution of Grifols products worldwide.

via alphather.com

Any questions, please drop me a line.

******************************************************
Follow us on:

Blogger:
http://4nursing.blogspot.com/

Facebook:
http://www.nursefriendly.com/facebook

Linked In:
http://www.linkedin.com/in/nursefriendly

Nursing Entrepreneurs, Nurses In Business
http://nursingentrepreneurs.ning.com/

Twitter!
http://www.nursefriendly.com/twitter

StumbleUpon,
http://www.nursefriendly.com/stumbleupon
******************************************************

Sincerely,

Andrew Lopez, RN
Nursefriendly, Inc. A New Jersey Corporation.
38 Tattersall Drive, Mantua New Jersey 08051
http://www.nursefriendly.com info@nursefriendly.com ICQ #6116137
856-415-9617, (fax) 415-9618

150,000 + Nurse-Reviewed & Approved Nursing Links

http://www.4nursing.com
http://www.howtostartanursingagency.com
http://www.jocularity.com
http://www.nursinghumor.com
http://www.nursefriendly.com
http://www.nursingentrepreneurs.com
http://www.nursingexperts.com

At MedImmune, we seek to develop innovative, high-value products in which we have significant interest, both independently and in collaboration with our partners. By creating cutting-edge biological products, we're improving health, enhancing lives and helping to make a world of difference.

Synagis^® (palivizumab) is the only monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease. Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.
MedImmune is dedicated to assisting patients with access to support and resources. To learn more, click here.
To learn more about Synagis, click here for Important Safety & Prescribing Information.

Approved Synagis Distribution Network Members
Approved Physician Purchase Channel Distributors

Wholesale Accounts
AmerisourceBergen
Cardinal
H.D. Smith
McKesson
Morris Dickson

FluMist^® (Influenza Vaccine Live, Intranasal) is the first and only nasal spray flu vaccine approved in the United States to help prevent influenza and is indicated for the active immunization of eligible individuals 2 to 49 years of age against influenza disease caused by influenza virus subtypes A and B contained in the vaccine.